Trial Profile
Cognitive effects of darifenacin and oxybutynin extended release in volunteers aged 60 and over
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Jul 2007
Price :
$35
*
At a glance
- Drugs Darifenacin (Primary) ; Oxybutynin
- Indications Overactive bladder
- Focus Pharmacodynamics
- Sponsors Novartis
- 12 Jul 2007 Status changed from in progress to completed.
- 10 Dec 2005 New trial record.